The third decade marks an important milestone for Pharex as a brand and company. In recent years, significant changes have occurred, with the company joining RiteMED and UNILAB for a bigger endeavor.
April 22, 2019
In partnership with the Philippine Urological Association (PUA), Pharex Health Corp. recently launched Pharex Tamsulosin, a drug intended for the management of lower urinary tract symptoms caused by benign prostatic hyperplasia or BPH, commonly known as the enlargement of the prostate.
The launch was held at the Unilab Bayanihan Center in Mandaluyong City, which gathered more than 200 doctor participants who are mostly urologists, internists, and family medicine specialists from UST, PGH, East Avenue Medical Center, VMMC and the National Kidney and Transplant Institute or NKTI.
Your browser does not support the video tag.
Dr. Gavino Mercado, President of the Philippine Urological Association, delivered the opening remarks while former PUA president, Dr. Rufino Agudera, provided a lecture on the latest information and medical management of BPH. The event also served as a venue for the participating physicians to earn their Continuing Professional Development (CPD) and Continuing Medical Education (CME) units and at the same time raise their awareness and technical knowledge on the detection and treatment of the disease. Dr. Diosdado Limjoco and Dr. Aristotle Roque, both PUA officers, acted as moderators during the learning session.
Attendees were treated with sumptuous meals and were entertained with great music by PURA band, a group composed of urology residents from various hospitals affiliated with the Philippine Urological Association. They also enjoyed their time at the photo booth for souvenir pictures and were given each a flash drive as giveaway.